CRBP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CR

Mkt Cap

$87.2M

Volume

996.83K

Next Earnings

November 11th

Loading chart

CR

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBP

Pay with—

Available Balance0.00

CR

Mkt Cap

$83.7M

Volume

996.83K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Corbus Pharmaceuticals to Participate in Upcoming Investor ConferencesCorbus Pharmaceuticals announced that CEO Yuval Cohen will present a corporate overview and participate in investor meetings at the RBC Capital Markets Global Healthcare Conference (May 19-20, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The clinical-stage company is developing CRB-701, an antibody drug conjugate for Nectin-4-expressing tumors, and CRB-913, an obesity treatment candidate.GlobeNewswire Inc. · May 13, 2026

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate UpdateCorbus Pharmaceuticals announced FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with a registrational study expected to launch this summer. The company completed enrollment in its CANYON-1 Phase 1b study of CRB-913 for obesity treatment with topline data expected summer 2026. Q1 2026 net loss was $23.0 million with $138.2 million in cash expected to fund operations into 2028.GlobeNewswire Inc. · May 12, 2026

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences ConferenceCorbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage oncology and obesity company, announced that CEO Yuval Cohen will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company's pipeline includes CRB-701 (antibody drug conjugate), CRB-601 (anti-integrin monoclonal antibody), and CRB-913 (CB1 inverse agonist for obesity treatment), which recently demonstrated a favorable safety profile and emerging evidence of weight loss in Phase 1a studies.GlobeNewswire Inc. · Feb 12, 2026

Corbus Pharmaceuticals Announces Pricing of Public OfferingCorbus Pharmaceuticals has priced a public offering of 4,744,231 common stock shares and pre-funded warrants, raising approximately $75 million to fund clinical development and corporate purposes.Benzinga · Oct 31, 2025

Corbus Pharmaceuticals Announces Pricing of Public OfferingCorbus Pharmaceuticals plans to raise approximately $75 million through a public offering of 4,744,231 common stock shares and pre-funded warrants, with proceeds intended to fund clinical development and working capital.GlobeNewswire Inc. · Oct 31, 2025

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25Corbus Pharmaceuticals announced promising Phase 1/2 clinical trial results for CRB-701, an antibody-drug conjugate targeting Nectin-4, showing robust response rates across head and neck, cervical, and urothelial cancers with a favorable safety profile.GlobeNewswire Inc. · Oct 18, 2025

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightThe cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.GlobeNewswire Inc. · Jul 10, 2025

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceCorbus Pharmaceuticals, a clinical-stage company focused on oncology and obesity, announced that its CEO will provide a corporate update and participate in investor meetings at the Jefferies Global Healthcare Conference.GlobeNewswire Inc. · May 22, 2025

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate, has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.GlobeNewswire Inc. · Jun 1, 2024

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual MeetingNORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.GlobeNewswire Inc. · May 23, 2024

to start trading

CR

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBP

Pay with—

Available Balance0.00

Your PositionYou don't own any CRBP yet.

Related Tickers

Earnings